Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
42.96
-0.79 (-1.81%)
Aug 1, 2025, 4:00 PM - Market closed
Kymera Therapeutics Employees
Kymera Therapeutics had 188 employees as of December 31, 2024. The number of employees increased by 1 or 0.53% compared to the previous year.
Employees
188
Change (1Y)
1
Growth (1Y)
0.53%
Revenue / Employee
$313,218
Profits / Employee
-$1,281,287
Market Cap
3.01B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 188 | 1 | 0.53% |
| Dec 31, 2023 | 187 | 20 | 11.98% |
| Dec 31, 2022 | 167 | 26 | 18.44% |
| Dec 31, 2021 | 141 | 66 | 88.00% |
| Dec 31, 2020 | 75 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KYMR News
- 5 weeks ago - Kymera Therapeutics Announces Pricing of $250 Million Public Offering - GlobeNewsWire
- 5 weeks ago - Kymera Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 5 weeks ago - Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics - Reuters
- 5 weeks ago - Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update - GlobeNewsWire
- 5 weeks ago - Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders - Business Wire
- 2 months ago - Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial - Barrons
- 2 months ago - Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data - Seeking Alpha
- 2 months ago - Kymera Stock Jumps. New Dermatitis Pill Could Challenge Regeneron Blockbuster. - Barrons